Serum asprosin levels and bariatric surgery outcomes in obese adults

Wang, Chao-Yung; Lin, Tien-An; Liu, Keng-Hau; Liao, Chien‐Hung; Liu, Yuyin; Wu, Victor Chien‐Chia; Wen, Ming‐Shien; Yeh, Ta‐Sen

doi:10.1038/s41366-018-0248-1

Cited by 94 publications

(83 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acara et al 19 suggested that asprosin might be a novel biochemical marker for predicting the severity of acute coronary syndrome with unstable angina pectoris. Wang et al 20 showed that higher asprosin concentrations before bariatric surgery were associated with the weight reduction magnitude at 6 months after surgery. More pathophysiological roles of asprosin require further study.…”

Section: Discussionmentioning

confidence: 99%

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus

Zhang

Jiang

et al. 2019

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction Asprosin is a novel secreted adipokine that is induced by fasting and promotes hepatic glucose release. In healthy humans, circulating asprosin shows circadian oscillation with an acute drop coinciding with the onset of eating. The present study investigated whether this circadian oscillation still exists in patients with type 2 diabetes mellitus. Materials and Methods We recruited 60 patients with type 2 diabetes mellitus and 60 individuals with normal glucose tolerance (NGT). All participants completed a 75‐g oral glucose tolerance test. Fasting and 2‐h postprandial serum asprosin concentrations were measured by the enzyme‐linked immunosorbent assay method. Partial correlation coefficients were calculated to analyze the relationships between serum asprosin level and parameters of glucose metabolism. Multiple logistic regression analysis was used to determine the association of serum asprosin level with diabetes. Results Both fasting and postprandial asprosin levels were significantly higher in patients with type 2 diabetes mellitus. The postprandial asprosin level was apparently lower than fasting asprosin level in individuals with NGT. The fasting asprosin level closely correlated with type 2 diabetes mellitus after multiple adjustment (odds ratio 2.329, P = 0.023). Asprosin correlated negatively with change in blood glucose (r = −0.502, P < 0.001) and change in C‐peptide (r = −0.467, P < 0.001) in individuals with NGT, but not in type 2 diabetes mellitus patients. Conclusions Serum asprosin level decreased coinciding with the onset of the oral glucose tolerance test in individuals with NGT, whereas this circadian oscillation was disturbed in type 2 diabetes mellitus patients. The impaired response of asprosin to glucose fluctuation in type 2 diabetes mellitus patients might be one of the reasons for the onset of type 2 diabetes mellitus.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus

Zhang

Jiang

et al. 2019

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…Wang et al reported that serum asprosin levels decreased significantly in obese patients who had bariatric surgery. They also reported that serum asprosin level was the only independent predictor for the percentage of weight loss after bariatric surgery . Uğur and Aydın investigated serum asprosin levels in obese patients and compared them with healthy control children.…”

Section: Discussionmentioning

confidence: 99%

“…There have been several studies that investigated serum asprosin levels in obese patients. Wang et al reported that serum asprosin levels decreased significantly 6 months after bariatric surgery . Ugur and Aydın investigated serum and saliva asprosin levels among individuals who were underweight, normal weight, overweight, and obese; they reported that asprosin levels increased coherent with the body mass index (BMI) .…”

mentioning

confidence: 99%

Increased serum circulating asprosin levels in children with obesity

Silistre¹,

Hatipoğl²

2020

Pediatrics International

View full text Add to dashboard Cite

Background: Childhood obesity is a growing and significant problem worldwide. Asprosin is a novel adipokine that is significantly associated with glucose and insulin production in the liver during fasting. In the present study, we aimed to demonstrate whether there would be differences between obese, overweight, and normal weight children in terms of serum asprosin levels. Methods: Forty-four children with obesity, 54 overweight children, and 60 normal weight children were compared in terms of serum asprosin levels and other anthropometric, biochemical, and hormonal parameters that are associated with being overweight and with obesity. Results: Serum asprosin levels were found to be significantly different between groups: 70.903 AE 17.49 ng/mL, 79.744 AE 29.54 ng/mL, and 106.293 AE 122.69 ng/mL in normal weight, overweight, and obese children respectively. Post-hoc analysis revealed that the asprosin level was significantly higher in obese children compared with normal weight children (P = 0.009). Additionally, asprosin was found to be a predictor of obesity in multiple regression analysis. Conclusion: Our study is the first to demonstrate increased levels of asprosin in obese children compared with normal weight children. Further studies are needed to demonstrate the role of asprosin in the etiology of childhood obesity, as well as other diseases that might be associated with effects of asprosin.

show abstract

“…Numerous studies have reported increased asprosin concentrations in humans and mice with obesity. It has been reported that serum asprosin levels are pathologically elevated in obese adults, children, and mice, while reduced body weight and food intake could be observed in obese mice via using an asprosin-specific antibody (6,23,24). Furthermore, a positive association can be seen between circulating asprosin concentrations and waist circumference and triglyceride (TG) (14,24).…”

Section: Asprosin In Obesitymentioning

confidence: 99%

“…Specifically, this study found that the pre-surgical asprosin levels in effective-responder patients (the percentage of body weight loss within 6 months after surgery >55%) were significantly higher than non-responders (the percentage of body weight loss within 6 months after surgery <35%). The sensitivity and specificity for asprosin levels to predict effective-responders were 76% and 75%, respectively (23). Interestingly, a study by Ma et al investigated the therapeutic effects of AM6545, a peripheral cannabinoid receptor neutral antagonist, on hypometabolic and hypothalamic obesity induced by monosodium glutamate (MSG).…”

Section: Asprosin In Obesitymentioning

confidence: 99%

Asprosin: A Novel Player in Metabolic Diseases

Yuan

Zhu

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

Asprosin, a novel glucogenic adipokine, is encoded by two exons (exon 65 and exon 66) of the gene Fibrillin 1 (FBN1) and mainly synthesized and released by white adipose tissue during fasting. Asprosin plays a complex role in the central nervous system (CNS), peripheral tissues, and organs. It is involved in appetite, glucose metabolism, insulin resistance (IR), cell apoptosis, etc. In this review, we will summarize the newly discovered roles of asprosin in metabolic diseases including diabetes, obesity, polycystic ovarian syndrome (PCOS), and cardiovascular disease (CVD), which may contribute to future clinical diagnosis and treatment.

show abstract

Serum asprosin levels and bariatric surgery outcomes in obese adults

Cited by 94 publications

References 27 publications

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus

Increased serum circulating asprosin levels in children with obesity

Asprosin: A Novel Player in Metabolic Diseases

Contact Info

Product

Resources

About